Vaccine in sentence

824 examples of Vaccine in a sentence

Though a vaccine for pneumococcal infection – a leading cause of pneumonia – was developed at the turn of the century, it is not included in routine immunization programs in five of the countries where pneumonia is most pervasive (Chad, China, India, Indonesia, and Somalia).

For HIV, the focus has been on pre-exposure prophylaxis and on developing a vaccine.

Likewise, a $100 million annual increase in spending to develop a vaccine against HIV/AIDS would generate substantial benefits in the future.

Here, the panel finds that spending just $122 million could achieve complete Hepatitis B vaccine coverage and avert about 150,000 annual deaths from the disease.

In fact, smallpox is the deadliest disease known to humanity; until Edward Jenner developed the vaccine in 1796, it was the leading cause of death in Europe.

Optimistically, Brazilian officials believe that the government’s Growth Acceleration Program will serve as a vaccine against global turbulence and help reduce bottlenecks in the economy.

Thanks to the advent of a vaccine and cheap drugs, TB kills very few people in the developed world nowadays.

We have also worked with the WHO to secure some 900,000 doses of oral cholera vaccine (OCV), an internationally accepted tool to prevent and control outbreaks.

Moreover, where the private sector does play an essential role – vaccine development – it has little incentive to devote resources to diseases that afflict the poor or poor countries.

Indeed, it appears that with more public funding, an Ebola vaccine could have been developed years ago.

The British physician Andrew Wakefield’s vaccine theory became wildly popular among parents, many of whom began to withhold vaccination (thus subjecting their own and other children to the risk of entirely preventable, and sometimes serious, illnesses).

Founded in 2000 by a partnership of major donors, international agencies, and vaccine industry leaders, Gavi’s goal is to help the world’s poorest countries introduce new lifesaving vaccines and strengthen their immunization programs.

Or will fiscal pressures lead, in some countries, to vaccine shortages, to declines in immunization coverage, or even, in the worst case, to vaccines being dropped altogether from national programs, reversing the hard-won gains of recent years?

One reason that there is no proven cure or vaccine for Ebola hemorrhagic fever is the wiliness of crossover diseases.

In the late 1990s, anti-vaccine sentiment manifested itself in a backlash against the measles, mumps, and rubella vaccine.

Similarly, a 2004 New York Academy of Medicine survey indicated that twice as many people were worried about the side effects of the well-established smallpox vaccine as were concerned about the disease itself.

The British pharmaceutical company GlaxoSmithKline recently announced that, together with the US National Institute of Allergy and Infectious Diseases, it is developing an experimental vaccine for Ebola.

With two more trial stages to go, the vaccine would not be ready for deployment before 2015.

Thanks to the development and deployment of a low-cost vaccine, the lives of hundreds of thousands of children have been saved, and communities that might otherwise have been devastated by the illness are thriving.

The mission was simple: to develop an affordable vaccine to fight meningitis A in Africa.

In less than ten years, the MenAfriVac vaccine was launched and has produced an immediate and dramatic break in the cycle of meningitis A epidemics.

By 2020, the vaccine is expected to protect more than 400 million people – preventing one million cases of meningitis A, 150,000 deaths from the disease, and 250,000 cases of severe disability among survivors.

Last year, the WHO approved MenAfriVac for use in regular vaccine schedules, making it possible for millions more to be protected.

Adults in whom the vaccine has worn off or is not 100% effective are increasingly getting sick.

In middle-income countries, prices would more closely reflect a country’s ability to pay (for example, GSK cut the price of its cervical cancer vaccine, Cervarix, by 60% in the Philippines and gained a 14-fold increase in volume sales).

Vaccinating Against an HIV ReboundBRIGHTON – When I began my career as an HIV activist in Botswana two decades ago, the thought of a vaccine seemed fanciful.

Even after the country hosted vaccine trials in the mid-2000s, many of us on the frontlines of the fight against HIV doubted that such a breakthrough would ever happen.

While these findings are preliminary and the sample size small, it is nonetheless exciting to imagine that the world may be on the verge of a viable vaccine.

This history suggests that even with a vaccine, many complex social, economic, and cultural issues will continue to complicate the war on HIV.

We must think carefully about how to introduce a vaccine without unintentionally encouraging “rebound effects,” like the re-emergence of practices that expose people to HIV infection.

Related words